AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22447014 — intervention group
Group type: COMPARATOR
Intervention: Control group (angiotensin receptor blocker and thiazide diuretic)
Number of subjects: 207
Study 19687338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 3,375 with hot flashes)
Number of subjects: 48335
Study 19687338 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 3,375 with hot flashes)
Number of subjects: 48335
Study 19687338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 45,160 without hot flashes)
Number of subjects: 48335
Study 19687338 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 45,160 without hot flashes)
Number of subjects: 48335
Study 19687338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 48335
Study 19687338 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48335
Study 17524942 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 500 (500 mg single oral dose)
Number of subjects: 0
Study 17524942 — intervention group
Group type: COMPARATOR
Intervention: CellCept (500 mg single oral dose)
Number of subjects: 0
Study 15205961 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Lifting (WL) for 60 min at 70‐75% of 1‐RM
Number of subjects: 10
Study 15205961 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (R) for 60 min at 70‐75% of maximal oxygen intake
Number of subjects: 10
Study 15205961 — intervention group
Group type: COMPARATOR
Intervention: No exercise (C)
Number of subjects: 10
Study 11986597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intrapleural hypotonic cisplatin treatment (50 microg/mL in distilled water for 15 minutes)
Number of subjects: 49
Study 11986597 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 49
Study 9772139 — intervention group
Group type: EXPERIMENTAL
Intervention: corn oil
Number of subjects: 14
Study 9772139 — intervention group
Group type: EXPERIMENTAL
Intervention: beef tallow
Number of subjects: 14
Study 9772139 — intervention group
Group type: EXPERIMENTAL
Intervention: rice bran oil
Number of subjects: 14
Study 9772139 — intervention group
Group type: EXPERIMENTAL
Intervention: canola oil
Number of subjects: 14
Study 9772139 — intervention group
Group type: EXPERIMENTAL
Intervention: olive oil
Number of subjects: 14
Study 9772139 — intervention group
Group type: EXPERIMENTAL
Intervention: all dietary phases pooled
Number of subjects: 14
Study 7648281 — intervention group
Group type: EXPERIMENTAL
Intervention: Live recombinant vaccinia virus expressing HIV envelope protein gp160LAI (HIVAC-1e) plus 640 micrograms recombinant baculovirus-expressed gp160LAI in alum (boosted 1-13 months later)
Number of subjects: 10
Study 7648281 — intervention group
Group type: EXPERIMENTAL
Intervention: Live recombinant vaccinia virus expressing HIV envelope protein gp160LAI (HIVAC-1e)
Number of subjects: 10
Study 7648281 — intervention group
Group type: COMPARATOR
Intervention: Subunit gp160LAI (640 micrograms in alum, 4 immunizations at 0, 1, 6, and 12 months)
Number of subjects: 10
Study 7648281 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (5 total)
Number of subjects: 10
Study 2699994 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 to 0.5 micrograms daily)
Number of subjects: 16
Study 2699994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Duogastrone (carbenoxolone sodium) 50 mg qid for 6 weeks
Number of subjects: 152
Study 603844 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules qid for 6 weeks
Number of subjects: 152
Study 603844 — intervention group
Group type: EXPERIMENTAL
Intervention: Duogastrone (carbenoxolone sodium)
Number of subjects: 152
Study 603844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 31278996 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy (BBT)
Number of subjects: 185
Study 31278996 — intervention group
Group type: COMPARATOR
Intervention: Assisted Referral to Care (ARC)
Number of subjects: 185
Study 30990549 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace wellness program (8 modules focused on nutrition, physical activity, stress reduction)
Number of subjects: 32974
Study 30990549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wellness programming)
Number of subjects: 32974
Study 29243795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant LH (r‐LH) added to recombinant FSH (r‐FSH) in the late follicular phase starting the same day of GnRH-antagonist administration.
Number of subjects: 66
Study 25880966 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise on a home trainer equipped with gaming elements (exergaming)
Number of subjects: 130
Study 25880966 — intervention group
Group type: COMPARATOR
Intervention: Non-aerobic intervention (stretching, flexibility and relaxation exercises)
Number of subjects: 130
Study 23859743 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotless anastomosis with barbed suture (V‐Loc™ 180; Covidien)
Number of subjects: 60
Study 23859743 — intervention group
Group type: COMPARATOR
Intervention: Knot-tying anastomosis with 3/0 polyglactin sutures (Polysorb(®); Covidien)
Number of subjects: 60
Study 21890753 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 65
Study 21890753 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 65
Study 19649649 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10 RM(Rel)
Number of subjects: 12
Study 19649649 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10 RM(Abs)
Number of subjects: 12
Study 17623719 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 g of EPA + DHA daily
Number of subjects: 27
Study 17623719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15154664 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy before 90 days after surgery
Number of subjects: 590
Study 15154664 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after 90 days after surgery
Number of subjects: 590
Study 15154664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with CMF regimens and radiotherapy before 90 days after surgery
Number of subjects: 590
Study 15154664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with CMF regimens and radiotherapy after 90 days after surgery
Number of subjects: 590
Study 15154664 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall local failure rate for group A
Number of subjects: 590
Study 15154664 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall local failure rate for group B
Number of subjects: 590
Study 11402634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release metformin hydrochloride tablets
Number of subjects: 0
Study 11402634 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release metformin hydrochloride product
Number of subjects: 0
Study 9511024 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein/energy supplementation
Number of subjects: 0
Study 9511024 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc, folate, and magnesium supplementation during gestation
Number of subjects: 0
Study 9511024 — intervention group
Group type: COMPARATOR
Intervention: Nutritional interventions (various types)
Number of subjects: 0
Study 8582130 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose taken at the beginning of the test meal
Number of subjects: 24
Study 8582130 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose taken 15 min after starting the test meal
Number of subjects: 24
Study 8582130 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose taken 30 min before the test meal
Number of subjects: 24
Study 8582130 — intervention group
Group type: COMPARATOR
Intervention: Control meal (no drug)
Number of subjects: 24
Study 2172884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy of 30 Gy
Number of subjects: 91
Study 2172884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy of 50 Gy
Number of subjects: 91
Study 2172884 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 91
Study 2172884 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (30 Gy, 50 Gy, and chemotherapy alone)
Number of subjects: 91
Study 720236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 75 mg dipyridamol and 330 mg acetylsalicylic acid, three times daily by mouth
Number of subjects: 101
Study 720236 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid alone at the same dosage
Number of subjects: 101
Study 30874860 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 31
Study 30874860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 28100203 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exposure treatment with diaphragmatic breathing (six cycles per minute)
Number of subjects: 29
Study 28100203 — intervention group
Group type: COMPARATOR
Intervention: VR exposure treatment without diaphragmatic breathing
Number of subjects: 29
Study 25546032 — intervention group
Group type: COMPARATOR
Intervention: Ankle-brachial index (ABI)
Number of subjects: 479
Study 25546032 — intervention group
Group type: COMPARATOR
Intervention: Maximum interartery differences (MIAD) in systolic blood pressures
Number of subjects: 479
Study 24352397 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT technique for alignment and leveling
Number of subjects: 70
Study 24352397 — intervention group
Group type: COMPARATOR
Intervention: Normal occlusion group
Number of subjects: 70
Study 24352397 — intervention group
Group type: COMPARATOR
Intervention: Malocclusion group
Number of subjects: 70
Study 21435203 — intervention group
Group type: EXPERIMENTAL
Intervention: POCT-assisted diagnosis
Number of subjects: 369
Study 21435203 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnosis
Number of subjects: 369
Study 19474138 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ferrous sulfate
Number of subjects: 219
Study 19474138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 17276712 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5mg chewable tablet once daily for 8 weeks)
Number of subjects: 50
Study 17276712 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen (1mg for 8 weeks)
Number of subjects: 50
Study 15191819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dissection of perforators (DIEP flap)
Number of subjects: 14
Study 15191819 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact rectus abdominis muscles)
Number of subjects: 14
Study 15569871 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (10, 20, 40, 80, 120, or 160 microg/kg; n=6 per group)
Number of subjects: 48
Study 15569871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 48
Study 10954759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen per day
Number of subjects: 309
Study 10954759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day
Number of subjects: 309
Study 10954759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 9077373 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (more than 800 g pure ethanol annually)
Number of subjects: 1924
Study 9077373 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (weekend drinkers)
Number of subjects: 1924
Study 9077373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDLc (mean 0.94 mmol L‐1)
Number of subjects: 1924
Study 9077373 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal HDLc (mean 1.25 mmol L‐1)
Number of subjects: 1924
Study 9077373 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 1924
Study 8365006 — intervention group
Group type: EXPERIMENTAL
Intervention: Otovent device used three times a day for 3 months
Number of subjects: 85
Study 8365006 — intervention group
Group type: COMPARATOR
Intervention: Observation group (control)
Number of subjects: 85
Study 2941770 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg)
Number of subjects: 20
Study 2941770 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg)
Number of subjects: 20
Study 2941770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (100 mg)
Number of subjects: 20
Study 2941770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2756308 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque
Number of subjects: 71
Study 2756308 — intervention group
Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 71
Study 31622944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of Post‐Rape Stress (PPRS)
Number of subjects: 233
Study 31622944 — intervention group
Group type: COMPARATOR
Intervention: Pleasant Imagery and Relaxation Information (PIRI)
Number of subjects: 233
Study 31622944 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 233
Study 31011807 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR (Blood Flow Restriction)
Number of subjects: 14
Study 31011807 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP (Hypoxia)
Number of subjects: 14
Study 31011807 — intervention group
Group type: EXPERIMENTAL
Intervention: HBFR (Hypoxia + Blood Flow Restriction)
Number of subjects: 14
Study 31011807 — intervention group
Group type: COMPARATOR
Intervention: NOR (Normoxia)
Number of subjects: 14
Study 31011807 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR
Number of subjects: 14
Study 28433432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose-Rate Prostate Brachytherapy (LDR-PB) boost
Number of subjects: 398
Study 28433432 — intervention group
Group type: COMPARATOR
Intervention: Dose-Escalated External Beam Radiation Therapy (DE-EBRT) boost
Number of subjects: 398
Study 25262788 — intervention group
Group type: EXPERIMENTAL
Intervention: niosomal methylene blue (NMB) gel
Number of subjects: 11
Study 25262788 — intervention group
Group type: COMPARATOR
Intervention: unloaded (free) methylene blue (FMB) gel
Number of subjects: 11
Study 24164685 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary vein approach
Number of subjects: 48
Study 24164685 — intervention group
Group type: COMPARATOR
Intervention: Subclavian vein approach
Number of subjects: 48
Study 21190450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous freshly isolated bone marrow cell transplantation (BMC-Tx)
Number of subjects: 56
Study 21190450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cell therapy)
Number of subjects: 56
Study 19614907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (Vit E)
Number of subjects: 150
Study 19614907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 17211875 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal profiles in MDD patients
Number of subjects: 141
Study 17211875 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD patients with depressive personality disorder
Number of subjects: 141
Study 14759620 — intervention group
Group type: EXPERIMENTAL
Intervention: Filshie clip
Number of subjects: 40
Study 14759620 — intervention group
Group type: COMPARATOR
Intervention: Falope ring
Number of subjects: 40
Study 11253866 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 11253866 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 0
Study 11253866 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn
Number of subjects: 0
Study 9539056 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac monotherapy
Number of subjects: 150
Study 9539056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with Tramadol-retard and Naproxen
Number of subjects: 150
Study 7925788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior adaptation to a grating pattern moving at between 1.5 and 4 cycles.s‐1 for 8 seconds
Number of subjects: 0
Study 7925788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to a flickering stimulus at a temporal frequency of 3.2 cycles.s‐1
Number of subjects: 0
Study 7925788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior adapting gratings with varying contrast
Number of subjects: 0
Study 7925788 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion‐dependent adaptive effect
Number of subjects: 0
Study 7925788 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker‐dependent effect
Number of subjects: 0
Study 2510677 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30 IU) administered by intravenous bolus injection over 2 to 5 minutes
Number of subjects: 116
Study 2510677 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK) (1.5 million IU) administered by intravenous infusion over 60 minutes
Number of subjects: 116
Study 2510677 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 116
Study 2510677 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 116
Study 803252 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant MOPP chemotherapy with irradiation
Number of subjects: 213
Study 803252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Adjuvant MOPP chemotherapy with irradiation)
Number of subjects: 213
Study 803252 — intervention group
Group type: COMPARATOR
Intervention: Control group (without adjuvant MOPP chemotherapy)
Number of subjects: 213
Study 31532358 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive weaning (NIV)
Number of subjects: 364
Study 31532358 — intervention group
Group type: COMPARATOR
Intervention: Invasive weaning
Number of subjects: 364
Study 28691581 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐min showering at ∼40°C before lights out
Number of subjects: 11
Study 28691581 — intervention group
Group type: COMPARATOR
Intervention: Normal sleeping conditions (control)
Number of subjects: 11
Study 26117212 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP plus health education
Number of subjects: 180
Study 26117212 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 23982674 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 0
Study 23982674 — intervention group
Group type: COMPARATOR
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 0
Study 21762268 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT7 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 7 days)
Number of subjects: 199
Study 21762268 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT14 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 14 days)
Number of subjects: 199
Study 19995253 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable subcuticular sutures (polyglytone 6211, Caprosyn)
Number of subjects: 47
Study 19995253 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable interrupted sutures (polybutester, Novafil)
Number of subjects: 47
Study 17259206 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg orally
Number of subjects: 32
Study 17259206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 14679326 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered ibuprofen (800 mg ibuprofen + 200 mg magnesium hydroxide)
Number of subjects: 20
Study 14679326 — intervention group
Group type: COMPARATOR
Intervention: Conventional ibuprofen (800 mg ibuprofen)
Number of subjects: 20
Study 11694865 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Disease Preventive Protocol including oral physiotherapy, non-alcoholic 0.05% fluoride mouthwashes, and topical application of myconazole oral gel
Number of subjects: 12
Study 11694865 — intervention group
Group type: COMPARATOR
Intervention: Instructions on oral physiotherapy
Number of subjects: 12
Study 9503766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral techniques
Number of subjects: 19
Study 8056235 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stents with side-holes (SH)
Number of subjects: 70
Study 8056235 — intervention group
Group type: COMPARATOR
Intervention: Biliary stents without side-holes (NSH)
Number of subjects: 70
Study 3134468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg
Number of subjects: 8
Study 3134468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg with aspirin 1 g
Number of subjects: 8
Study 3134468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3134468 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 1 g
Number of subjects: 8
Study 30070379 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed outreach plus patient navigation
Number of subjects: 1800
Study 30070379 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed outreach alone
Number of subjects: 1800
Study 30070379 — intervention group
Group type: COMPARATOR
Intervention: Usual care with visit-based screening
Number of subjects: 1800
Study 30070379 — intervention group
Group type: COMPARATOR
Intervention: Mailed outreach groups (both outreach and outreach/navigation)
Number of subjects: 1800
Study 28969399 — intervention group
Group type: EXPERIMENTAL
Intervention: Open end ureteral catheter insertion prior to PNL
Number of subjects: 50
Study 28969399 — intervention group
Group type: COMPARATOR
Intervention: No catheter insertion prior to PNL
Number of subjects: 50
Study 26228589 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 135
Study 26228589 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office balloon dilation
Number of subjects: 135
Study 26228589 — intervention group
Group type: COMPARATOR
Intervention: Standalone balloon dilation
Number of subjects: 135
Study 24433565 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Guided Imagery (IGI)
Number of subjects: 35
Study 24433565 — intervention group
Group type: COMPARATOR
Intervention: Digital storytelling (DS)
Number of subjects: 35
Study 21915653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued participants
Number of subjects: 202